In support of this hypothesis, certain inflammatory cytokines that are increased in patients with MPN, including TNFα and interferon α (IFNα), have been shown to confer a selective growth advantage to JAK2V617F‐mutant over wild‐type cells in vitro,17, 18 enabling clonal expansion (Fig 1). The gene discussed is TNF; the disease is myeloproliferative disorder.